Cyp asx

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia, cyp asx.

Morningstar Investor users sign in here. Skip to Content. Market Centre. United States. Market Report. ASX Market Report.

Cyp asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre. ASX rulebooks. ASX Compliance. ASX regulatory framework. Public consultations. Code of practice.

All content on FT. Discover Investments.

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast MCA to manufacture cell therapy products, including mesenchymal stem cells , on a commercial scale. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Financial Times Close. Search the FT Search.

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow Volatile share price over the past 3 months. Shareholders have been diluted in the past year. Currently unprofitable and not forecast to become profitable over the next 3 years.

Cyp asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance.

Cintia song

Investment Ideas. Investment products. Past Performance. Cancel Continue. Volatile share price over the past 3 months. BPH Energy Ltd. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Your password should be characters Invalid password: this word has been flagged as unsuitable for use as a secure password. Morningstar Investment Management. All content on FT. DLT as a Service.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved.

IDT Australia Limited. Alterity Therapeutics Ltd. Price AUD 0. Any information that you receive via FT. Cancel Continue. For Asset Managers. Future Growth. Contact Us. Featured Products and Services. Lumos Diagnostics Holdings Ltd. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Cynata Therapeutics Limited. Data as of Mar 08